Search results
Results from the WOW.Com Content Network
Ribavirin's amide group can make the native nucleoside drug resemble adenosine or guanosine, depending on its rotation. For this reason, when ribavirin is incorporated into RNA, as a base analog of either adenine or guanine, it pairs equally well with either uracil or cytosine, inducing mutations in RNA-dependent replication in RNA viruses ...
Ribavirin: Hepatitis C [15] nucleoside analogue reverse transcriptase inhibitor: Rilpivirine (Edurant) [16] HIV Rimantadine: Influenza A: M2 proton channel antagonist Ritonavir: HIV HIV-1 protease inhibitor Saquinavir: HIV Simeprevir (Olysio) Hepatitis C Sofosbuvir: Hepatitis C [17] nucleoside analogue reverse transcriptase inhibitor: Stavudine ...
It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active.
In adults, ribavirin is used off-label and is generally reserved for the severely immunocompromised, such as those undergoing hematopoietic stem cell transplants. [ 3 ] Presatovir , an experimental antiviral drug, has shown promising results in clinical trials but has not yet been approved for medical use.
Ribavirin, or tribavirin Index of chemical compounds with the same molecular formula This set index page lists chemical structure articles associated with the same molecular formula .
Gastrointestinal disturbances (including mouth ulcers, indigestion, diarrhea, constipation, etc.) Infections (including sinusitis, the flu, sepsis, UTIs, etc.)
Ribavirin is one medication which has shown good potential for the treatment of HPIV-3 given recent in-vitro tests (in-vivo tests show mixed results). [12] Ribavirin is a broad-spectrum antiviral, and as of 2012, was being administered to those who are severely immuno-compromised, despite the lack of conclusive evidence for its benefit. [12]
In patients who received peginterferon alfa-2a and ribavirin for a year, the addition of telaprevir for 24 weeks achieved an SVR of 53% compared to 14% in patients who did not receive telaprevir. In that study, shorted treatment with only three months of telaprevir and six months of treatment peginterferon alfa-2a and ribavirin achieved an SVR ...